



24th August 2020

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai 400 001

The Secretary
The National Stock Exchange of India
Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra East,
Mumbai 400 050

Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

Dear Sirs

The unaudited financial results of the Company for the quarter and half year ended 30th June 2020 were approved by the Board of Directors of the Company at its meeting held on 28th July 2020 and published on 30th July 2020. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half year ended 30th June 2020 in the format specified in the applicable accounting standards.

Kindly take the above information on record.

Thanking you,

Yours faithfully

For SANOFI INDIA LIMITED

GIRISH TEKCHANDANI
COMPANY SECRETARY

Related Party Disclosures**i. Parties where control exists:**

- a) Sanofi S.A. France, ultimate holding Company
- b) Hoechst GmbH, Germany, holding Company

ii. Other related parties in Sanofi Group where common control exists and with whom transactions have taken place during the period.

Sanofi-Aventis Singapore Pte. Limited
 Francopia S.A.R.L.
 Sanofi-Aventis Deutschland GmbH
 Sanofi-Aventis Groupe S.A.
 Sanofi Lanka Limited
 Sanofi Chimie S.A
 Sanofi Pasteur India Private Limited
 Sanofi-Synthelabo (India) Private Limited
 Sanofi Winthrop Industrie S.A.
 Sanofi-Aventis Pakistan Limited
 Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited)
 Sanofi India Limited Provident Fund
 * No transactions during the year

iii. Key management personnel of the Company for the year

Mr. Rajaram Narayanan - Managing Director
 Mr. Charles Billard - Whole Time Director and CFO
 Mr. Cherian Mathew - Whole Time Director
 Mr. Girish Tekchandani - Company Secretary

iv. Non-Executive Directors

Mr. Thomas Rouckout (upto 25th February 2020)
 Mr. Cyril Grandchamp-Desraux
 Dr. Shailesh Ayyangar (upto 25th February 2020)

v. Independent Directors

Mr. Aditya Narayan
 Mr. Rangaswamy R. Iyer (upto 30th March 2020)
 Mrs. Usha Thorat

vi. Transactions during the year

(₹ in Million)

Particulars	June 30, 2020
Ultimate Holding Company	
Dividend paid	-
Holding Company	
Dividend paid	-
Other related Parties	
Sale of Products	
Sanofi-Aventis Singapore Pte. Limited	3,370
Others	456
Total	3,826
Purchase of Raw Materials and Traded Goods	
Sanofi-Aventis Singapore Pte. Limited	3,460
Others	360
Total	3,820
Expenses recharged to other companies	
Sanofi-Aventis Groupe S.A.	5
Total	5
Sale of Services	
Sanofi-Synthelabo (India) Private Limited	550
Sanofi Pasteur India Private Limited	87
Sanofi Winthrop Industrie S.A.	69
Others	23
Total	730
Rent Income	
Sanofi-Synthelabo (India) Private Limited	*
Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited)	*
Total	*
Rent Paid	
Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited)	*
Loans given	
Sanofi Pasteur India Private Limited	400
Interest income on loans	
Shantha Biotechnics Private Limited	192
Sanofi Pasteur India Private Limited	3
Total	196

Particulars	June 30, 2020
Expenses recharged by other companies	
Sanofi-Synthelabo (India) Private Limited	54
Sanofi Lanka Limited	23
Total	77
Contribution to In-house Trust for Post Employment Benefits - Provident Fund	
Sanofi India Limited Provident Fund #	149
Payment towards Intangibles under development	
Sanofi-Synthelabo (India) Private Limited	2
Key Management Personnel Remuneration	
Remuneration	
Mr. Rajaram Narayanan	20
Mr. Charles Billard	10
Mr. Girish Tekchandani	6
Mr. Cherian Mathew	13
Total	49
Share based benefit	
Mr. Rajaram Narayanan	7
Mr. Cherian Mathew	1
Mr. Charles Billard	3
Total	10
Sitting Fees to Independent Directors	
Mr. Aditya Narayan	*
Mr. Rangaswamy R. Iyer	*
Ms. Usha Thorat	*
Dr. Shailesh Ayyangar	*
Total	1
Commission to Independent Directors ##	
Mr. Aditya Narayan	1
Mr. Rangaswamy R. Iyer	*
Ms. Usha Thorat	*
Dr. Shailesh Ayyangar	*
Total	2

* denotes figure less than a million

Including contribution by employees.

Provisions made for half year ended 30th June 2020

Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the year six month ended June 30, 2020, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

vii. Outstanding as at June 30, 2020

(₹ in Million)

Particulars	June 30, 2020
Other related Parties	
Trade Receivables	
Sanofi-Aventis Singapore Pte. Limited	645
Sanofi-Synthelabo (India) Private Limited	87
Others	92
Total	824
Trade Payables	
Sanofi-Aventis Singapore Pte. Limited	1,309
Francopia S.A.R.L.	168
Others	143
Total	1,620
Others Payables	
Sanofi-Aventis Singapore Pte. Limited	35
Total	35
Loans receivable	
Sanofi Healthcare India Private Limited (Formerly Shantha Biotechnics Private Limited) #	4,450
Sanofi Pasteur India Private Limited *	400
Total	4,850

#Loans given to Shantha Biotechnics Private Limited at the rate of interest of 9.5% p.a. (7.5 % w.e.f April 15, 2020)

Maximum balance outstanding during the year ₹ 4,450 Million

The said loans have been proposed to be utilized by Shantha Biotechnics Private Limited for business purpose.

The Loans have been given against corporate guarantee by Sanofi S.A. (Ultimate Holding Company. The Maturity Date of same is April 15, 2021).

*Loans given to Sanofi Pasteur India Private Limited at the rate of interest of 9.5% p.a.

Maximum balance outstanding during the year ₹ 400 Million (December 31, 2019 : Nil)

The said loans have been proposed to be utilized by Sanofi Pasteur India Private Limited for business purpose.

The Loans have been given against corporate guarantee by Sanofi S.A. (Ultimate Holding Company. The Maturity Date of same is April 15, 2021).